221 related articles for article (PubMed ID: 37725308)
21. Anticholinergic Burden and Associated Healthcare Resource Utilization in Older Adults with Overactive Bladder.
Jaggi A; Nazir J; Fatoye F; Quelen C; Tu X; Ali M; Siddiqui E; Covernton PJO; Landeira M; Choudhury N
Drugs Aging; 2021 Oct; 38(10):911-920. PubMed ID: 34386936
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and β3-adrenoceptor agonists.
Okui N
World J Urol; 2019 Nov; 37(11):2459-2466. PubMed ID: 30687908
[TBL] [Abstract][Full Text] [Related]
23. Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder.
Blais AS; Nadeau G; Moore K; Genois L; Bolduc S
Eur Urol; 2016 Jul; 70(1):9-13. PubMed ID: 26876327
[TBL] [Abstract][Full Text] [Related]
24. A drug safety evaluation of mirabegron in the management of overactive bladder.
Robinson D; Thiagamoorthy G; Cardozo L
Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
[TBL] [Abstract][Full Text] [Related]
25. Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder.
Araklitis G; Robinson D; Cardozo L
Clin Interv Aging; 2020; 15():1493-1503. PubMed ID: 32921995
[TBL] [Abstract][Full Text] [Related]
26. Drug therapy for an overactive bladder.
Thiagamoorthy G; Cardozo L; Srikrishna S
Womens Health (Lond); 2015 Jul; 11(4):445-8. PubMed ID: 26238677
[No Abstract] [Full Text] [Related]
27. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
Wagg A; Cardozo L; Nitti VW; Castro-Diaz D; Auerbach S; Blauwet MB; Siddiqui E
Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.
Gratzke C; Chapple C; Mueller ER; Robinson D; Rolland C; Staskin D; Stoelzel M; Maanen RV; Siddiqui E
Eur Urol; 2019 Dec; 76(6):767-779. PubMed ID: 31416636
[TBL] [Abstract][Full Text] [Related]
29. [Comprehensive pharmacologic management of overactive bladder].
Krivoborodov GG; Tur EI
Urologiia; 2017 Apr; (1):82-88. PubMed ID: 28394529
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
[TBL] [Abstract][Full Text] [Related]
31. Despite Recommendations, Anticholinergics Account for the Majority of Prescriptions to Treat Overactive Bladder in the United States.
Carr DN; Macharia A; Hacker MR; Winkelman WD
Urogynecology (Phila); 2023 May; 29(5):497-503. PubMed ID: 36730660
[TBL] [Abstract][Full Text] [Related]
32. Healthcare and economic burden of anticholinergic use in adults with overactive bladder: a systematic literature review.
Duperrouzel C; Martin C; Mendell A; Bourque M; Carrera A; Mack A; Nesheim J
J Comp Eff Res; 2022 Dec; 11(18):1375-1394. PubMed ID: 36354285
[No Abstract] [Full Text] [Related]
33. Vibegron, a Novel Potent and Selective β
Yoshida M; Takeda M; Gotoh M; Nagai S; Kurose T
Eur Urol; 2018 May; 73(5):783-790. PubMed ID: 29366513
[TBL] [Abstract][Full Text] [Related]
34. What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?
Caremel R; Loutochin O; Corcos J
Int Urogynecol J; 2014 Feb; 25(2):165-70. PubMed ID: 23922008
[TBL] [Abstract][Full Text] [Related]
35. Mirabegron: β3-adrenergic receptor agonist for the treatment of overactive bladder.
Bridgeman MB; Friia NJ; Taft C; Shah M
Ann Pharmacother; 2013; 47(7-8):1029-38. PubMed ID: 23757386
[TBL] [Abstract][Full Text] [Related]
36. Vibegron for the treatment of overactive bladder: a comprehensive update.
Gleicher S; Sebesta EM; Reynolds WS; Dmochowski R
Expert Opin Pharmacother; 2022 Sep; 23(13):1479-1484. PubMed ID: 36124780
[TBL] [Abstract][Full Text] [Related]
37. Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women.
Geller EJ; Crane AK; Wells EC; Robinson BL; Jannelli ML; Khandelwal CM; Connolly A; Parnell BA; Matthews CA; Dumond JB; Busby-Whitehead J
Clin Drug Investig; 2012 Oct; 32(10):697-705. PubMed ID: 22873491
[TBL] [Abstract][Full Text] [Related]
38. Health Resource Utilization and Cost for Patients with Incontinent Overactive Bladder Treated with Anticholinergics.
Yehoshua A; Chancellor M; Vasavada S; Malone DC; Armstrong EP; Joshi M; Campbell K; Pulicharam R
J Manag Care Spec Pharm; 2016 Apr; 22(4):406-13. PubMed ID: 27023694
[TBL] [Abstract][Full Text] [Related]
39. No. 353-Treatments for Overactive Bladder: Focus on Pharmacotherapy - An Addendum.
Geoffrion R
J Obstet Gynaecol Can; 2017 Dec; 39(12):1221-1229. PubMed ID: 28986184
[TBL] [Abstract][Full Text] [Related]
40. Risks of Dementia After Treatment with an Anticholinergic, Beta-3 Agonist, or Combination of Both for an Overactive Bladder: A Korean National Cohort Study.
Park JS; Choi SB; Jang WS; Kim J; Ham WS
Eur Urol Focus; 2024 Feb; ():. PubMed ID: 38388215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
